[1] Tabulation on the 2000 population census of the People′s Republic of China Vol ⅡI(中国2010年人口普查资料,第三卷) (K). 2010. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.html.
[2] Children′s Hospital of Chongqing Medical University. Rational Medication for Pediatric Diseases(临床药物治疗学:儿科疾病)[M]. Chapter 1. Beijing: People′s Medical Publishing House, 2011:1.
[3] LI Y J, YANG S M. Analysis and evaluation of medicines of children′s in national essential medicine list[J]. Chin Pharm Aff (中国药事), 2014, 28(4):349-351.
[4] SOHI H, SULTANA Y, KHAR R K. Taste masking technologies in oral pharmaceuticals: recent developments and approaches[J]. Drug Develop Ind Pharm, 2004, 30(5):429-448.
[5] LEGIN A, RUDNITSKAYA A, CLAPHAM D, et al. Electronic tongue for pharmaceutical analytics: quantification of tastes and masking effects[J]. Anal Bioanal Chem, 2004, 380(1):36-45.
[6] LI X L, QIU J X, LIU R X, et al. Changes of fingerprints of radix gentianae before and after taste masking[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2013, 19(17):104-106.
[7] REN S L, WANG Y J, ZHENG Y, et al. Taste masking and evaluation based on the mechanism of bitterness[J]. Cent South Pharm (中南药学), 2014, 12(6):562-566.
[8] DONYA A, HETTIARACHCHY N S, LIYANAGE R, et al. Effects of processing methods on the proximate composition and momordicosides K and L content of bitter melon vegetable[J]. J Agric Food Chem, 2007, 55(14):5827-5833.
[9] CHUNG H S, LEE S Y. Modification of ginseng flavors by bitter compounds found in chocolate and coffee[J]. J Food Sci, 2012, 77(6):202-210.
[10] ZHAO H Y. Study on masking technology of coptis chinensis extract[J]. Heilongjiang Med J (黑龙江医药), 2016, 29(4):605-607.
[11] KAYUMBA P C, TWAGIRUMUKIZA M, HUYGHEBAERT N, et al. Taste-masked quinine sulphate pellets: bio-availability in adults and steady-state plasma concentrations in children with uncomplicated plasmodium falciparum malaria[J]. Ann Tropic Paediatr, 2008, 28(2):103-109.
[12] WALSH J, CRAM A, WOERTZ K, et al. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients[J]. Adv Drug Deliv Rev, 2014, 73: 14-33.
[13] PATIL H, FENG X, MAJUMDAR S, et al. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach[J]. Am Assoc Pharm Sci J, 2014, 17(1):194-205.
[14] RAYMOND Y, CHAMPAGNE C P. Dissolution of lipid-based matrices in simulated gastrointestinal solutions to evaluate their potential for the encapsulation of bioactive ingredients for foods[J]. Int J Food Sci, 2014:Article ID 749630.
[15] HUANG S, MAO C, WILLIAMS R O 3^rd, et al. Solubility advantage (and disadvantage) of pharmaceutical amorphous solid dispersions[J]. J Pharm Sci, 2016, 105(12):3549-3561.
[16] BOHIN M C, ROLAND W S, GRUPPEN H, et al. Evaluation of the bitter-masking potential of food proteins for EGCG by a cell-based human btter taste receptor assay and binding studies[J]. J Agric Food Chem, 2013, 61(42):10010-10017.
[17] WILDE S C, KEPPLER J K, PALANI K, et al. β-Lactoglobulin as nanotransporter for allicin: sensory properties and applicability in food[J]. Food Chem, 2016, 199: 667-674.
[18] SHAH P P, MASHRU R C. Palatable reconstitutable dry suspension of artemether for flexible pediatric dosing using cyclodextrin inclusion complexation[J]. Pharm Develop Technol, 2010, 15(3):276-285.
[19] BREWSTER M E, LOFTSSON T. Cyclodextrins as pharmaceutical solubilizers[J]. Adv Drug Deliv Rev, 2007, 59(7):645-666.
[20] XIANG Z Y, LI X F, ZHU N, et al. Preparation of the resin complexes masking bitterness of gentianae radix total glycosides extract[J]. Chin Tradit Pat Med (中成药), 2016, 38(4):785-790.
[21] WOERTZ K, TISSEN C, KLEINEBUDDE P, et al. Rational development of taste masked oral liquids guided by an electronic tongue[J]. Int J Pharm, 2010, 400(1-2):114-123.
[22] KULKARNI M G, MENJOGE A R. pH Sensitive polymer and process for preparation thereof: United States, 7531612[P]. 20090512.
[23] ALAYOUBI A, DAIHOM B, ADHIKARI H, et al. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin amberlite IRP 69 for use in pediatrics[J]. Drug Develop Ind Pharm, 2016, 42(10):1579-1589.
[24] MARTIN DEL CALLE E M. Cyclodextrins and their uses: a review[J]. Proc Biochem, 2004, 39(9):1033-1046.
[25] MULLER R H, PETERS K, BECKER R, et al. Nanosuspension for the i.v. administration of poorly soluble drugs—stability during sterilization and long-term storage[C]. Proceedings of the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, Controlled Release Society, 1995:574-575.
[26] PINNAMANENI S, DSA N G, DSA S K. Formulation approaches for orally administered poorly soluble drugs[J]. Pharmazie, 2002, 57(5):291-300.
[27] LIVERSIDGE G G, CUNDY K C, BISHOP J, et al. Surface modified drug nanoparticles: United States, 5145684[P]. 19920614.
[28] MULLER R H, BECKER R, KRUSS B, et al. Pharmaceutical nanosuspensions for medical administration as system of increased saturation solubility and rate of solution: United States, 5858410[P]. 19950523.
[29] TIWARY A K. Modification of crystal habit and its role in dosage form performance[J]. Drug Develop Ind Pharm, 2001, 27(7):600-709.
[30] MAGHSOODI M. Role of solvents in improvement of dissolution rate of drugs: crystal habit and crystal agglomeration[J]. Adv Pharm Bull, 2015, 5(1):13-18.
[31] MARRARO G A. Perspectives for use of surfactant in children and adult[J]. J Mater-Fetal & Neonat Med, 2004, 16(2):29-31.
[32] FABIANO V, MAMELI C, ZUCCOTTI G V. Paediatric pharmacology: remember the excipients[J]. Pharm Res, 2011, 63(5):362-365.
[33] SALUNKE S, BRANDYS B, GIACOIA G, et al. The STEP (safety and toxicity of excipients for paediatrics) database: part 2-the pilot version[J]. Int J Pharm, 2013, 457(1):310-322.
[34] SCADDING G. Pediatric allergy medications: review of currently available formulations[J]. Curr Med Res Opin, 2009, 25(5):2069-2079.
[35] STRICKLEY R G, IWATA Q, WU S, et al. pediatric drugs-a review of commercially available oral formulations[J]. J Pharm Sci, 2008, 97(5):1731-1774.
[36] SUN G N, REN Q, LI J, et al. New measures in preparation of orally disintegrating tablets[J]. Chin J Pharm (中国医药工业杂志), 2008, 39(11):866-869.
[37] LU Y, JIN Y B, WANG S M, et al. Property evaluation of co-processed excipient of mannitol and polyplasdone and its application in orally disintegrating tablets[J]. Chin Pharm J (中国药学杂志), 2016, 51(9):715-722.
[38] LI F, LI B L, WANG J Z, et al. Preparation and quality control of famotidine effervescent tablets[J]. Chin J Mod Appl Pharm (中国现代应用药学), 2011, 28(4):335-337.
[39] LIANG A M, LIN H Q. Clarithromycin dry suspension and its preparation method: China, 200410027712.9[P]. 20050316.
[40] ZAJICEK A, FOSSLER M J, BARRETT J S, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms[J]. Am Assoc Pharm Sci J, 2013, 15(4):1072-1081.
[41] PERUMAL O, MURTHY S N, KALIA Y N. Turning theory into practice: the development of modern transdermal drug delivery systems and future trends[J]. Skin Pharmacol Physiol, 2013, 26(4-6):331-342.
[42] GOLDSTEIN J, SMITH T R, PUGACH N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine[J]. Headache, 2012, 52(9):1402-1410.
[43] VINCKEN W, DEKHUIJZEN R, BARNES P, et al. The ADMIT series-Issues in Inhalation Therapy. 4) How to choose inhaler devices for the treatment of COPD[J]. Primary Care Respir J, 2010, 19(1):10-20.